Skip to content
Open menu Close menu

Dr Mark Sutherland

PositionSenior Experimental Officer
DepartmentInstitute of Cancer Therapeutics
Telephone+44 (0) 1274 235841
EmailM.Sutherland@bradford.ac.uk

Administrative Responsibilities

  • Faculty of Life Sciences Genetically Modified Organisms Committee
  • Editorial board member of Cervical Cancer Open Access Journal
  • Review editor of Frontiers in MicroBioTechnology

Study History

  • BSc (Microbiology) University of Cape Town, South Africa 1988
  • BSc (Hons) University of Stellenbosch, South Africa 1989
  • MSc University of Stellenbosch, South Africa 1993
  • PhD (rer med) Charite – Campus Benjamin Franklin, Berlin, Germany 1997 – 2000

Research Areas

  • Development and validation of tumour models for the preclinical evaluation of novel anticancer therapeutics
  • Genetically modified models over-expressing the target at relevant possibly clinical levels
  • Expression and purification of the target enzymes for in vitro high throughput screening of lead compounds

Current Projects

I am currently working on the core projects, namely:

  • Anti-cancer agents targeting the tumour cell glycocalyx (Dr. R. Falconer),
  • Drug metabolising enzymes (Dr. K. Pors),
  • Antagonists of ß3 Integrins as Modulators of Tumour Progression and Angiogenesis (Dr. H. Sheldrake)

Publications

  • Vinader V, Sadiq M, Sutherland M, Huang M, Loadman PM, Elsalem L, Shnyder SD, Cui H, Afarinkia K, Searcey M, Patterson L, Pors K. 2015. Probing cytochrome P450-mediated activation with a truncated azinomycin analogue. Med Chem Commun.6: 187-191
  • Bachran C, Bachran S, Sutherland M, Bachran D, Fuchs K. 2014. Preclinical studies of saponins for tumor therapy. Recent advances in Medicinal Chemistry. 1:272-302
  • Al-Saraireh YM, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, Loadman PM, Errington RJ, Smith PJ, Fukuda M, Gerardy-Schahn R, Patterson LH, Shnyder SD, Falconer RA. 2013. Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. PLoS One. 8:e73366
  • Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K. 2013. Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. J. Med. Chem. 56(15):6273-6277
  • Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. 2013. Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human bladder cancer. Mol. Cancer Ther. 12(1):27-37
  • Sutherland M, Shnyder SD, Gordon A, Patterson LH and Sheldrake HM. 2012. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects. Cancers. 4:1106-1145. ISSN 2072-6694
  • Pors, K., Loadman, P.M., Shnyder, S.D., Sutherland, M., Sheldrake, H.M., Guino, M., Kiakos, K., Hartley, J.A., Searcey, M., "Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity," Chem Commun (Camb). (2011) Nov 28;47(44):12062-4. Epub 2011 Oct 14. PubMed PMID: 22002321
  • Bachran, C., Schneider, S., Riese, S.B., Bachran, D., Urban, R., Schellmann, N., Zahn, Sutherland, M. and Fuchs, H. (2011) "A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin," Life Sciences 88:226-232
  • Bachran, C., Dürkop, H., Sutherland, M., Bachran, D., Muller, C., Weng, A., Melzig, M.F. and Fuchs, H. (2009) "Inhibition of tumour growth by targeted toxins in mice is dramatically improved by Saponinum Album in a synergistic way," J Immunother 32(7):713-725
  • Sutton C.W, Sutherland M, Shnyder S, Patterson L.H. 2010, Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics 2010 Jan (2):327-31
  • Fuchs H, Bachran C, Li T, Heisler I, Durkop H, and Sutherland M2007, A Cleavable Molecular adapter reduces side effects and concomitantly enhances efficacy in tumour treatment by targeted toxins in mice.  J. Control release 117 (3):342-350.
  • Bachran C, Sutherland M, Heisler I, Hebestreit P, Melzig MF and Fuchs H. 2006. The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin¿s structure. Experimental Biology and Medicine. 231(4): 412-420.
  • Fuchs H, Bachran C, Heisler I and Sutherland M. 2005. A closer look at protein transduction domains as a tool in drug delivery. Current Nanosciences 1(2):117-124.
  • Bachran C, Heisler I, Fuchs Hand, Sutherland M. 2005. Influence of protein transduction domains on target-specific chimeric proteins. Biochem Biophys Res Commun. 337(2):602-609.
  • Heisler I, Keller J, Tauber R, Sutherland M and Fuchs H. 2003. A cleavable adapter to reduce non-specific cytotoxicity of recombinant immunotoxins. Int. J. Cancer. 103(2):277-282.

Share this

Upcoming events

View all events »